Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marcella McGuffin

Physician Assistant, Medical Ashland, KY Physician Assistant

NPI 1891747432 CMS profile 10517557

2930 Carter Ave, Ashland, KY 41101

Open in the dashboard

General payments

$7,205

475 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcella McGuffin of Ashland, KY is reported in the CMS Open Payments database as having received $7,205 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,131 65
2024 General $1,387 74
2023 General $1,052 65
2022 General $1,571 111
2021 General $2,063 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcella McGuffin
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Marcella McGuffin were reported at $1,131. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Marcella McGuffin Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,063 $156 $41–$563 $132
2022 $1,571 $185 $55–$649 $149
2023 $1,052 $199 $58–$717 $160
2024 $1,387 $206 $62–$740 $164
2025 $1,131 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,424 104 payments
  2. Novo Nordisk Inc $1,291 90 payments
  3. Lilly USA, LLC $1,016 66 payments
  4. Sanofi-Aventis U.S. LLC $386 25 payments
  5. Kowa Pharmaceuticals America, Inc. $315 25 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $302 21 payments
  7. Dexcom, Inc. $293 11 payments
  8. AstraZeneca Pharmaceuticals LP $283 18 payments
  9. AbbVie, Inc. $281 16 payments
  10. Amarin Pharma Inc. $245 20 payments
  11. Other $1,370 79 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,194 474 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,167 82 payments
  2. Ozempic $1,156 81 payments
  3. FreeStyle Libre 3 $667 40 payments
  4. FreeStyle Libre $469 39 payments
  5. JARDIANCE $382 23 payments
  6. MOUNJARO $344 21 payments
  7. Livalo $315 25 payments
  8. FARXIGA $283 18 payments
  9. SYNTHROID $281 16 payments
  10. Dexcom G6 Transmitter $264 9 payments
  11. Other $3,580 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

6,026

Median for Physician Assistant: 241

Drug cost

$2,147,328

Median for Physician Assistant: $4,110

Branded share of claims

48.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 312 $480,092
Mounjaro Tirzepatide Brand 145 $212,255
Jardiance Empagliflozin Brand 177 $193,832
Trulicity Dulaglutide Brand 117 $175,969
Farxiga Dapagliflozin Propanediol Brand 122 $135,378
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 85 $133,817
Tresiba Flextouch U-200 Insulin Degludec Brand 72 $120,376
Januvia Sitagliptin Phosphate Brand 44 $60,883
Tresiba Flextouch U-100 Insulin Degludec Brand 57 $59,550
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 26 $42,747

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$38,992

Medicare's payments for the services billed

Medicare patients

238

Average age 72

Services billed

1,011

147 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Arthritis 53%
Chronic kidney disease 42%
Ischemic heart disease 35%
Depression 29%
Heart failure 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $146
  • Boehringer Ingelheim Pharmaceuticals, Inc. $58
$204 177 —
RYBELSUS
  • Novo Nordisk Inc $125
$125 — —
Ozempic
  • Novo Nordisk Inc $125
$125 312 —
SYNTHROID
  • AbbVie, Inc. $70
$70 314 —
Korlym
  • Corcept Therapeutics $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record